← back to search

H. Phillip Koeffler

Duke-NUS Medical School · US
Area of research
Molecular Biology · Hematology
Research interest
Research interests include Acute Myeloid Leukemia Research, Retinoids in leukemia and cellular processes, Cancer-related Molecular Pathways, and RNA modifications and cancer.
h-index
122
citations
64,851
works
1,108
NIH funding
primary concept
email

Recent publications

Retraction Note: Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
2025cited by 0position: contributordoi
Supplementary Data from PINK1-Mediated Mitophagy Promotes Oxidative Phosphorylation and Redox Homeostasis to Induce Drug-Tolerant Persister Cancer Cells
2025cited by 0position: contributordoi
Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy
2025cited by 0position: contributordoi
Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer
Nature Communications 2024cited by 29position: middledoi
Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer.
2024cited by 15position: contributordoi
A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy.
2024cited by 2position: contributordoi
Data from A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy
2024cited by 1position: contributordoi
Supplementary Tables 1 from A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy
2024cited by 0position: contributordoi
Supplementary Table 5 from A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy
2024cited by 0position: contributordoi
Supplementary figures1 from A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy
2024cited by 0position: contributordoi
Data from A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy
2024cited by 0position: contributordoi
Supplementary figures1 from A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy
2024cited by 0position: contributordoi
Supplementary Tables 1 from A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy
2024cited by 0position: contributordoi
Supplementary Table 5 from A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy
2024cited by 0position: contributordoi
PINK1-Mediated Mitophagy Promotes Oxidative Phosphorylation and Redox Homeostasis to Induce Drug-Tolerant Persister Cancer Cells.
2023cited by 98position: contributordoi
Comprehensive analyses of partially methylated domains and differentially methylated regions in esophageal cancer reveal both cell-type- and cancer-specific epigenetic regulation
Genome biology 2023cited by 21position: middledoi
Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy.
2023cited by 16position: contributordoi
Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT).
2023cited by 15position: contributordoi
Data from PINK1-Mediated Mitophagy Promotes Oxidative Phosphorylation and Redox Homeostasis to Induce Drug-Tolerant Persister Cancer Cells
2023cited by 0position: contributordoi
Supplementary Data from PINK1-Mediated Mitophagy Promotes Oxidative Phosphorylation and Redox Homeostasis to Induce Drug-Tolerant Persister Cancer Cells
2023cited by 0position: contributordoi
Data from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy
2023cited by 0position: contributordoi
Data from PINK1-Mediated Mitophagy Promotes Oxidative Phosphorylation and Redox Homeostasis to Induce Drug-Tolerant Persister Cancer Cells
2023cited by 0position: contributordoi
Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy
2023cited by 0position: contributordoi
Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy
2023cited by 0position: contributordoi
Data from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy
2023cited by 0position: contributordoi
Supplementary Data from PINK1-Mediated Mitophagy Promotes Oxidative Phosphorylation and Redox Homeostasis to Induce Drug-Tolerant Persister Cancer Cells
2023cited by 0position: contributordoi
PINK1-Mediated Mitophagy Promotes Oxidative Phosphorylation and Redox Homeostasis to Induce Drug-Tolerant Persister Cancer Cells
Cancer Research 2022cited by 141position: middledoi
Overexpression of laminin-5 gamma-2 promotes tumorigenesis of pancreatic ductal adenocarcinoma through EGFR/ERK1/2/AKT/mTOR cascade
Cellular and Molecular Life Sciences 2022cited by 58position: middledoi
Transcriptome analysis identifies TODL as a novel lncRNA associated with proliferation, differentiation, and tumorigenesis in liposarcoma through FOXM1
Pharmacological Research 2022cited by 33position: middledoi
Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal squamous cell carcinoma microenvironment.
2021cited by 158position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

De‐Chen Lin · University of Southern California44 papers (2013–2025) · 32 papers (2019–2025)Anand Mayakonda · National University of Singapore23 papers (2016–2022)Ling‐Wen Ding · National University of Singapore23 papers (2013–2021)Liang Xu · Yunnan Academy of Forestry22 papers (2013–2025)Ling-Wen Ding · Guizhou University19 papers (2019–2025)Henry Yang · National University of Singapore16 papers (2013–2019)Jonathan Said · University of Pittsburgh15 papers (2012–2020)Zhentang Lao · National University Cancer Institute, Singapore15 papers (2023–2025)Henry Yang · National University Health System15 papers (2023–2025)Qiao-Yang Sun · Pediatrics and Genetics15 papers (2023–2025)Li Ying · Nanjing Medical University15 papers (2023–2025)Wee Joo Chng · Clinical Nutrition Research Centre15 papers (2023–2025)Deepika Kanojia · National University of Singapore14 papers (2013–2022)Benjamin P. Berman · Henderson Community College14 papers (2016–2023)Ngan Doan · Ronald Reagan UCLA Medical Center14 papers (2012–2020)Yan‐Yi Jiang · Second Hospital of Anhui Medical University13 papers (2014–2021)Sigal Gery · Cedars-Sinai Medical Center12 papers (2013–2024) · 11 papers (2021–2025)Vikas Madan · National University of Singapore10 papers (2013–2020)